Advertisement
Home Tags Drug Approvals

Tag: Drug Approvals

Adlyxin (lixisenatide)

FDA Approves Adlyxin for Type 2 Diabetes Mellitus

Once-daily injection to improve glycemic control, along with diet and exercise
Xiidra (lifitegrast) eye drops have been approved by the U.S. Food and Drug Administration to treat symptoms of dry eye disease.

FDA Approves Xiidra Eye Drops to Treat Dry Eye Disease

First approved lymphocyte function-associated antigen agonist
The once-daily acne treatment Differin Gel 0.1% (adapalene) has been approved for over-the-counter use among patients 12 and older

FDA Approves Differin Gel for Over-the-Counter Use

First OTC retinoid available for acne treatment among patients 12 and older
The ExAblate Neuro device has been approved by the U.S. Food and Drug Administration to deliver focused ultrasound to destroy tissue in a tiny area of the brain that is thought to be involved in essential tremor.

FDA Approves Ultrasound Device to Treat Essential Tremor

Focused ultrasound device to treat essential tremor in patients who have not responded to medication
The first coronary stent to be gradually absorbed by the body has been approved by the U.S. Food and Drug Administration.

FDA Approves First Absorbable Coronary Stent

Device is absorbed by the body after about three years
The Xpert Carba-R Assay diagnostic

FDA Approves New Test to Help Detect Drug-Resistant Bacteria

Uses specimens taken directly from patients; specifically looks for resistance to carbapenems
The combination drug Epclusa has been approved by the U.S. Food and Drug Administration to treat the six major strains of chronic hepatitis C virus.

FDA Approves Epclusa for Chronic Hepatitis C

Combination drug treats six major strains of hepatitis C virus infection
Ocaliva (obeticholic acid) has been approved by the U.S. Food and Drug Administration to treat primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with inadequate response to UDCA

FDA Approves Ocaliva for Primary Biliary Cholangitis

For patients who have not responded to, or cannot tolerate, ursodeoxycholic acid
The U.S. Food and Drug Administration has approved the first-ever buprenorphine implant to treat opioid dependence

FDA Approves Probuphine Implant for Opioid Dependence

New form of treatment designed to last six months
The U.S. Food and Drug Administration has approved the first-ever buprenorphine implant to treat opioid dependence

FDA Approves Probuphine Implant for Opioid Dependence

New form of treatment designed to last six months